Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
49 hedge funds and large institutions have $41.5M invested in Cidara Therapeutics in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 14 increasing their positions, 12 reducing their positions, and 11 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 12
0.08% less ownership
Funds ownership: 3.27% → 3.18% (-0.08%)
17% less funds holding
Funds holding: 59 → 49 (-10)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
49% less capital invested
Capital invested by funds: $81.7M → $41.5M (-$40.3M)
82% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$3.48M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$1.72M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$732K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$327K |
| 5 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$205K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.96M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2.89M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$1.32M |
| 4 |
Millennium Management
New York
|
-$807K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$409K |
CDTX Hedge Fund Activity: Q4 2018 in Review
49 of the 4,445 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q4 2018, worth a combined $41.5M — down 49% from $81.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of CDTX and 2 opened new positions — a net loss of 9 holders — while 12 trimmed existing stakes and 14 added.
The largest buyer was BVF Inc, adding an estimated $3.48M. The largest seller was Fidelity Investments, exiting entirely with an estimated $3.96M sold.
- 49 institutional investors held Cidara Therapeutics (CDTX) as of Q4 2018, down from 59 in Q3 2018.
- Funds reported $41.5M of Cidara Therapeutics stock for Q4 2018, down 49% quarter-over-quarter.
- 2 funds opened new Cidara Therapeutics positions in Q4 2018 and 11 closed out, a net change of -9 holders.
- The largest Cidara Therapeutics buyer in Q4 2018 was BVF Inc, an estimated $3.48M added.
- The largest Cidara Therapeutics seller in Q4 2018 was Fidelity Investments, an estimated $3.96M sold.
Based on aggregated 13F filings for Q4 2018.